← All trials
NCT06100627
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 14, 2023
- Primary completion
- Feb 5, 2024
- Completion date
- Feb 14, 2024
- First posted
- Oct 25, 2023
- Last posted
- Oct 25, 2023
- Enrollment
- 32
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Alebund Pty LtdLead sponsor
- Nucleus Network LtdOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.